GemPharmatech Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 1,590

Employees

  • Stock Symbol
  • 688046

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $4.03
  • (As of Friday Closing)

GemPharmatech General Information

Description

GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • No. 12, Xuefu Road
  • Jiangbei New District, Jiangsu Province
  • Nanjing, 210032
  • China
+86 025
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • No. 12, Xuefu Road
  • Jiangbei New District, Jiangsu Province
  • Nanjing, 210032
  • China
+86 025

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GemPharmatech Stock Performance

As of 20-Nov-2026, GemPharmatech’s stock price is $4.03. Its current market cap is $1.65B with 410M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.03 $4.35 $1.87 - $6.45 $1.65B 410M 9.9M $0.07

GemPharmatech Financials Summary

As of 30-Sep-2026, GemPharmatech has a trailing 12-month revenue of $137M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,201,494 775,581 592,361 1,012,069
Revenue 136,638 110,326 95,720 87,943
EBITDA 32,987 34,577 27,033 28,361
Net Income 29,430 19,835 15,305 22,462
Total Assets 433,480 409,488 352,412 363,625
Total Debt 31,119 41,636 18,148 17,158
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GemPharmatech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GemPharmatech‘s full profile, request access.

Request a free trial

GemPharmatech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and devel
Discovery Tools (Healthcare)
Nanjing, China
1,590 As of 2025

Santa Clara, CA
 

Rensselaer, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GemPharmatech Competitors (2)

One of GemPharmatech’s 2 competitors is Cyagen, a Venture Capital-Backed company based in Santa Clara, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cyagen Venture Capital-Backed Santa Clara, CA
Taconic Biosciences Private Equity-Backed Rensselaer, NY
You’re viewing 2 of 2 competitors. Get the full list »

GemPharmatech Patents

GemPharmatech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026061268-A1 Three-mutation alzheimer's disease mouse model, construction method, and use thereof Pending 20-Sep-2024
AU-2025206075-A1 Animal model and construction method therefor Pending 02-Jan-2024
EP-4835087-A1 Animal model and construction method therefor Pending 02-Jan-2024
WO-2025146085-A1 Animal model and construction method therefor Inactive 02-Jan-2024
AU-2025205864-A1 Animal model for producing humanized antibody and construction method therefor Pending 02-Jan-2024 A01K67/0278
To view GemPharmatech’s complete patent history, request access »

GemPharmatech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GemPharmatech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GemPharmatech‘s full profile, request access.

Request a free trial

GemPharmatech Investments & Acquisitions (2)

GemPharmatech’s most recent deal was a Merger/Acquisition with Baimai Biotechnology for . The deal was made on 16-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Baimai Biotechnology 16-Nov-2026 Merger/Acquisition Other Pharmaceuticals and Biotechnology
Pet Medtech 15-Dec-2024 Early Stage VC Drug Discovery
To view GemPharmatech’s complete investments and acquisitions history, request access »

GemPharmatech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view GemPharmatech’s complete esg history, request access »

GemPharmatech FAQs

  • When was GemPharmatech founded?

    GemPharmatech was founded in 2017.

  • Where is GemPharmatech headquartered?

    GemPharmatech is headquartered in Nanjing, China.

  • What is the size of GemPharmatech?

    GemPharmatech has 1,590 total employees.

  • What industry is GemPharmatech in?

    GemPharmatech’s primary industry is Discovery Tools (Healthcare).

  • Is GemPharmatech a private or public company?

    GemPharmatech is a Public company.

  • What is GemPharmatech’s stock symbol?

    The ticker symbol for GemPharmatech is 688046.

  • What is the current stock price of GemPharmatech?

    As of 20-Nov-2026 the stock price of GemPharmatech is $4.03.

  • What is the current market cap of GemPharmatech?

    The current market capitalization of GemPharmatech is $1.65B.

  • What is GemPharmatech’s current revenue?

    The trailing twelve month revenue for GemPharmatech is $137M.

  • Who are GemPharmatech’s competitors?

    Cyagen and Taconic Biosciences are competitors of GemPharmatech.

  • What is GemPharmatech’s annual earnings per share (EPS)?

    GemPharmatech’s EPS for 12 months was $0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process